Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most…
What’s next for Novo Nordisk’s obesity drug CagriSema
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Unstable tariff situation and new AI disruption spark market sell-off
Futures-options traders work on the floor at the New York Stock Exchange’s NYSE American (AMEX) in New York…
The market is so on edge about AI that it’s selling off Monday on an unlikely source
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…
Novo Nordisk sues Hims & Hers over compounded obesity drugs
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper,…
Stocks making the biggest moves midday: AMZN, CNC, RBLX
Check out the companies making headlines in midday trading. Centene — Shares of the health insurance provider slid…
Hims & Hers falls 8% after Novo’s legal threat. Here’s the latest
Rafael Henrique | SOPA Images | AP The stock of Hims & Hers dropped in premarket trading early…
Hims & Hers announces Wegovy pill copy; Novo Nordisk vows legal action
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
Thursday's big stock stories: What’s likely to move the market in the next trading session – CNBC
Thursday’s big stock stories: What’s likely to move the market in the next trading session CNBCJ Balvin & More…